Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
PW Medtech Group Limited (1358.HK)
Beijing, CN
Operating within the People's Republic of China, PW Medtech Group Limited is an investment holding company primarily engaged in the medical device industry. The company specializes in the manufacturing and distribution of a diverse portfolio of medical consumables, including various types of infusion sets such as non-PVC, precision filter, and light-resistant models, alongside intravenous cannula products and insulin needles and pens. Beyond its core medical device activities, the group also provides property management services. Established in 1997, the company, previously known as Pyholding Limited, maintains its corporate headquarters in Beijing, China.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -1.69% | -0.85% | +2.65% | -13.43% | -13.43% | -10.08% | +11.54% | +114.81% | +27.47% | -42.57% | -66.95% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 1 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Instruments & Supplies: +7.9%+7.1% Q4'25: +14.9% (vs Q4'23)
-
EPS growth Medical - Instruments & Supplies: +16.3%-36.0% Q4'25: -64.8% (vs Q4'23)
-
FCF margin FCF growth · Medical - Instruments & Supplies: +27.1%+15.7% Q4'25: +26.9% (vs Q4'23)
-
EBIT margin Medical - Instruments & Supplies: +13.5%+15.3% ★ Q4'25: +10.3% (vs Q4'23)
-
ROIC Medical - Instruments & Supplies: +6.0%+3.4% Q4'25: +4.3% (vs Q4'23)
-
Share dilution Medical - Instruments & Supplies: +0.1%-2.1% ★ Q4'25: -2.0% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Medical - Instruments & Supplies: -0.24×0.08× ★ Q4'25: 0.05× (vs Q4'23)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2013 actual |
Dec 2014 actual |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
|---|---|---|---|---|---|---|---|---|---|
| Revenue |
457.08M
est: 361.69M (+26.4%)
|
608.06M
est: 500.69M (+21.4%)
|
515.59M
est: 568.57M (-9.3%)
|
319.58M
est: 599.93M (-46.7%)
|
286.91M
est: 526.18M (-45.5%)
|
310.81M
est: 566.96M (-45.2%)
|
362.18M
est: 660.44M (-45.2%)
|
247.35M
est: 696.87M (-64.5%)
|
271.40M
est: 746.61M (-63.6%)
|
| EBITDA |
192.81M
est: 106.09M (+81.7%)
|
277.96M
est: 128.73M (+115.9%)
|
297.67M
est: 221.13M (+34.6%)
|
137.15M
est: 277.21M (-50.5%)
|
64.42M
est: 207.62M (-69.0%)
|
81.85M
est: 166.30M (-50.8%)
|
70.26M
est: 193.72M (-63.7%)
|
2.94M
est: 185.28M (-98.4%)
|
77.98M
est: 220.09M (-64.6%)
|
| EBIT |
172.40M
est: 59.70M (+188.8%)
|
239.79M
est: 130.61M (+83.6%)
|
239.69M
est: 191.27M (+25.3%)
|
117.53M
est: 211.99M (-44.6%)
|
44.70M
est: 97.11M (-54.0%)
|
61.81M
est: 93.58M (-34.0%)
|
40.86M
est: 109.01M (-62.5%)
|
-24.69M
est: 1.55M (-1,689.7%)
|
47.07M
est: 123.85M (-62.0%)
|
| Net Income |
77.91M
est: 75.27M (+3.5%)
|
176.63M
est: 85.93M (+105.5%)
|
208.58M
est: 158.05M (+32.0%)
|
109.14M
est: 184.15M (-40.7%)
|
4.52M
est: 153.14M (-97.0%)
|
114.81M
|
81.98M
est: 1.62B (-95.0%)
|
631.81M
est: 76.19M (+729.2%)
|
739.12M
est: 178.79M (+313.4%)
|
| SGA |
121.54M
est: 142.64M (-14.8%)
|
174.22M
est: 192.39M (-9.4%)
|
130.09M
est: 180.99M (-28.1%)
|
86.96M
est: 103.32M (-15.8%)
|
125.35M
est: 62.69M (+100.0%)
|
131.00M
est: 223.58M (-41.4%)
|
166.40M
est: 260.45M (-36.1%)
|
139.22M
est: 169.05M (-17.6%)
|
123.09M
est: 295.90M (-58.4%)
|
| EPS |
0.06
est: 0.05 (+27.9%)
|
0.11
est: 0.10 (+15.0%)
|
0.12
est: 0.11 (+8.2%)
|
0.07
est: 0.12 (-45.5%)
|
0.00
est: 0.14 (-97.9%)
|
0.07
|
0.05
|
0.40
est: 0.17 (+129.5%)
|
0.47
est: 0.18 (+155.1%)
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | A | 4/5 | 5/5 | 3/5 | 4/5 | 4/5 | 2/5 | 5/5 |
| 2026-05-28 | A | 4/5 | 5/5 | 3/5 | 4/5 | 4/5 | 2/5 | 5/5 |
| 2026-05-27 | A | 4/5 | 5/5 | 3/5 | 4/5 | 4/5 | 2/5 | 5/5 |
| 2026-05-26 | A | 4/5 | 5/5 | 3/5 | 4/5 | 4/5 | 2/5 | 5/5 |
| 2026-05-22 | A | 4/5 | 5/5 | 3/5 | 4/5 | 4/5 | 2/5 | 5/5 |
| 2026-05-21 | A | 4/5 | 5/5 | 3/5 | 4/5 | 4/5 | 2/5 | 5/5 |
| 2026-05-20 | A | 4/5 | 5/5 | 3/5 | 4/5 | 4/5 | 2/5 | 5/5 |
| 2026-05-19 | A | 4/5 | 5/5 | 3/5 | 4/5 | 4/5 | 2/5 | 5/5 |
| 2026-05-18 | A | 4/5 | 5/5 | 3/5 | 4/5 | 4/5 | 2/5 | 5/5 |
| 2026-05-15 | A | 4/5 | 5/5 | 3/5 | 4/5 | 4/5 | 2/5 | 5/5 |
| 2026-05-14 | A | 4/5 | 5/5 | 3/5 | 4/5 | 4/5 | 2/5 | 5/5 |
| 2026-05-13 | A | 4/5 | 5/5 | 3/5 | 4/5 | 4/5 | 2/5 | 5/5 |
| 2026-05-12 | A | 4/5 | 5/5 | 3/5 | 4/5 | 4/5 | 2/5 | 5/5 |
| 2026-05-11 | A+ | 4/5 | 5/5 | 3/5 | 4/5 | 4/5 | 3/5 | 5/5 |
| 2026-05-08 | A | 4/5 | 5/5 | 2/5 | 4/5 | 4/5 | 3/5 | 5/5 |
| 2026-05-07 | A | 4/5 | 5/5 | 2/5 | 4/5 | 4/5 | 3/5 | 5/5 |
| 2026-05-06 | A | 4/5 | 5/5 | 2/5 | 4/5 | 4/5 | 3/5 | 5/5 |
| 2026-05-05 | A | 4/5 | 5/5 | 2/5 | 4/5 | 3/5 | 3/5 | 5/5 |
| 2026-05-04 | A | 4/5 | 5/5 | 2/5 | 4/5 | 3/5 | 3/5 | 5/5 |
| 2026-04-30 | A | 4/5 | 5/5 | 2/5 | 4/5 | 3/5 | 3/5 | 5/5 |
| 2026-04-29 | A | 4/5 | 5/5 | 2/5 | 4/5 | 3/5 | 3/5 | 5/5 |
| 2026-04-28 | A | 4/5 | 5/5 | 2/5 | 4/5 | 3/5 | 3/5 | 5/5 |
| 2026-04-27 | A | 4/5 | 5/5 | 2/5 | 4/5 | 3/5 | 3/5 | 5/5 |
| 2026-04-24 | A | 4/5 | 5/5 | 2/5 | 4/5 | 3/5 | 3/5 | 5/5 |
| 2026-04-23 | A- | 4/5 | 5/5 | 2/5 | 4/5 | 2/5 | 3/5 | 5/5 |
| 2026-04-22 | A- | 4/5 | 5/5 | 2/5 | 4/5 | 2/5 | 3/5 | 5/5 |
| 2026-04-21 | A- | 4/5 | 5/5 | 2/5 | 4/5 | 2/5 | 3/5 | 5/5 |
| 2026-04-20 | A- | 4/5 | 5/5 | 2/5 | 4/5 | 2/5 | 3/5 | 5/5 |
| 2026-04-17 | A- | 4/5 | 5/5 | 2/5 | 4/5 | 2/5 | 3/5 | 5/5 |
| 2026-04-16 | A- | 4/5 | 5/5 | 2/5 | 4/5 | 2/5 | 3/5 | 5/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Yue'e Zhang | Executive Chairman & Chief Executive Officer | 1M | female |
| Ka Man So FCIS | Company Secretary | — | female |
| Tian Tian | Financial Director | — | female |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 1358.HK
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
